list.jobson.com
Open in
urlscan Pro
34.210.132.119
Public Scan
URL:
http://list.jobson.com//dm?id=17f4e26ff3e0d84c69dd5d3978ce219fe5082a7dd7dcbdea
Submission: On November 22 via api from US — Scanned from DE
Submission: On November 22 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
Get information on proper dosing to help prevent shingles in your patients. Patients look to you—do you have a plan in place for shingles vaccination? Get the dosing details you need to help protect your patients. Having trouble reading this email? Click here. This email is funded and developed by GSK. Prescribing Information SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox). Important Safety Information • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX See Important Safety Information CONTINUED BELOW Having trouble reading this email? Click here. This email is funded and developed by GSK. Prescribing Information SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox). Important Safety Information • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX See Important Safety Information CONTINUED BELOW › See DOSING DETAILS ›See DOSING DETAILS Make sure you and your team know the proper dosing schedule for SHINGRIX Dear wesley rumfelt, , Though you’re probably familiar with the dosing requirements for SHINGRIX, it never hurts to get a quick refresh. Having a plan in place to ensure patients complete the full 2-dose series may help prevent shingles.1 IF THEY ONLY RECEIVED ONE—THEY’RE NOT DONE The second dose of SHINGRIX should be administered anytime between 2 and 6 months after the first dose to complete the series.1 It’s important to encourage your patients to return by either using your in-house reminder system, or having them go to SHINGRIXreminder.com to sign up for text, email, or phone message reminders. Here are a few other things for you and your team to keep in mind. THE DOWNLOAD ON DOSING Make sure you and your team know the proper dosing schedule for SHINGRIX Dear wesley rumfelt, , Though you’re probably familiar with the dosing requirements for SHINGRIX, it never hurts to get a quick refresh. Having a plan in place to ensure patients complete the full 2-dose series may help prevent shingles.1 IF THEY ONLY RECEIVED ONE—THEY’RE NOT DONE The second dose of SHINGRIX should be administered anytime between 2 and 6 months after the first dose to complete the series.1 It’s important to encourage your patients to return by either using your in-house reminder system, or having them go to SHINGRIXreminder.com to sign up for text, email, or phone message reminders. Here are a few other things for you and your team to keep in mind. THE DOWNLOAD ON DOSING SHINGRIX is administered as a 2-dose series.1 SHINGRIX is supplied as an adjuvant and antigen for reconstitution.1 SHINGRIX should be refrigerated. DO NOT FREEZE: Store both the antigen and adjuvant between 2º and 8ºC (36º and 46ºF) before reconstitution (discard if frozen).1 SHINGRIX is a recombinant vaccine for intramuscular injection only.1 SHINGRIX is administered as a 2-dose series.1 SHINGRIX is supplied as an adjuvant and antigen for reconstitution.1 SHINGRIX should be refrigerated. DO NOT FREEZE: Store both the antigen and adjuvant between 2º and 8ºC (36º and 46ºF) before reconstitution (discard if frozen).1 SHINGRIX is a recombinant vaccine for intramuscular injection only.1 Learn more about dosing and administration. SEE DOSING DETAILS SEE DOSING DETAILS References: 1. Prescribing Information for SHINGRIX. Important Safety Information • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%) • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%) • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion • Vaccination with SHINGRIX may not result in protection of all vaccine recipients Important Safety Information • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%) • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%) • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion • Vaccination with SHINGRIX may not result in protection of all vaccine recipients Please see full Prescribing Information. This email is intended for US healthcare professionals only. You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967. Trademarks are owned by or licensed to the GSK group of companies. Please see full Prescribing Information. This email is intended for US healthcare professionals only. You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967. Trademarks are owned by or licensed to the GSK group of companies. ©2021 GSK or licensor. SGXEML210159 October 2021 Produced in USA. ©2021 GSK or licensor. SGXEML210159 October 2021 Produced in USA. Privacy Statement e-Pharm/alert was sent to you by /alert Marketing, Inc. 395 Hudson Street, 3rd Floor New York, NY 10014 Be sure to add epharmalert@alertmarketingmail.com to your address book. To change your address, reply to this message and give us your old and new address; type “Change of Address: e-Pharm/alert” in the subject line. Click here if you do not wish to receive further e-mails from e-Pharm/alert. Privacy Statement e-Pharm/alert was sent to you by /alert Marketing, Inc. 395 Hudson Street, 3rd Floor New York, NY 10014 Be sure to add epharmalert@alertmarketingmail.com to your address book. To change your address, reply to this message and give us your old and new address; type “Change of Address: e-Pharm/alert” in the subject line. Click here if you do not wish to receive further e-mails from e-Pharm/alert.